Immunotherapy

Durvalumab combined with transarterial chemoembolization and bevacizumab lengthened PFS among certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.

ANAHEIM, Calif. — Use of oral mucosal immunotherapy in the form of a toothpaste appeared safe and effective for the treatment of adults with peanut allergy, according to results of the placebo-controlled phase 1 OMEGA safety study.

ANAHEIM, Calif. — An additional 12 months of treatment with a skin patch-based approach to immunotherapy for peanut allergy increased the percentage of toddlers able to tolerate peanut, according to results of the EPOPEX study.

The safety of cephalosporins for patients with confirmed penicillin allergies has not been well studied, but they appeared to be safe in a small study.

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.

Healio compiled the most-read news in allergy, asthma and immunology posted in October.

The FDA approved pembrolizumab in combination with gemcitabine and cisplatin chemotherapy for adults with locally advanced unresectable or metastatic biliary tract cancer.

Text-based e-triage can select individuals for a fast-track process that allows them to proceed directly to infusion, saving as much as 66 minutes total care time, according to a study presented at ASCO Quality Care Symposium.

The FDA approved toripalimab-tpzi for two indications as treatment for nasopharyngeal carcinoma, making it the first approved therapy for this malignancy.

An estimated 10% to 40% of patients with solid tumors develop brain metastases.